Abstract
Hematopoietic cell transplantation is frontline treatment of multiple myeloma (MM).Autologous hematopoietic stem cell transplantation (auto-HSCT) could improve remission rate,prolong survival time,the tandem auto-HSCT is able to make patients get further benefits for patients not achieving at least very good partial remission after the first auto-HSCT.Allologous hematopoietic stem cell transplantation (alloHSCT) is potentially able to cure multiple myeloma,but patients achieve less benefit because of high transplant-related mortality (TRM).The TRM is low after reduced-intensity conditioning allo-HSCT,but which exhibit no survival benefit.Moreover,patients achieve no survival benefit after tandem auto-HSCT and allologous reduced-intensity conditioning transplantation.This paper reviewes recent studies about HSCT in MM. Key words: Multiple myeloma; Hematopoietic stem cell transplantation
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
